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responses were achieved in 27% (n=25) and 28% (n=8) 
of patients, respectively, over 52 weeks, and responses 
improved over time. Methotrexate was eﬀ ective for nail 
disease as measured by the Nail Psoriasis Severity Index.
Warren and colleagues’ results are similar to those 
obtained in trials comparing methotrexate to biological 
therapies, in which response to methotrexate was 45%.3 
These response rates are lower than the PASI 75 response 
rates of 60–80% and the PASI 90 response rates of 
44–60% reported with biological therapy, especially 
with inﬂ iximab, adalimumab, ustekinumab, and, more 
recently, the anti-interleukin-17 drugs secukinumab 
and ixekizumab.6–11 Unfortunately, the present study did 
not compare oral with subcutaneous administration. 
However, Warren and colleagues’ results compare 
favourably with those of a previous 52 week study 
showing PASI 75 responses to oral methotrexate 
(5–25 mg/week) of 24% and PASI 90 responses of 18%, 
suggesting that subcutaneous administration is superior 
to oral administration in the management of psoriasis.11 
Moreover, the biopsy results conﬁ rm the clinical eﬀ ect, 
showing reduction of inﬂ ammatory cells and reduction 
of T-helper-17 mediated cytokines.
The question that remains is whether methotrexate 
should remain the ﬁ rst-line systemic therapy for moderate 
to severe psoriasis. Because we now know that psoriasis 
is not just skin deep, and that many of the comorbidities, 
including psoriatic arthritis, metabolic syndrome, and 
cardiovascular events, in addition to premature death, are 
related to the extent of skin involvement, perhaps drugs 
that eﬀ ectively control inﬂ ammation should be used 
initially.12 This approach could only be addressed via long-
term observations of prospective studies of patients treated 
with methotrexate compared with those treated with 
biological therapy, with collection of information not only 
about clinical improvement of skin disease, but also about 
comorbidities. Warren and colleagues’ study provides 
information about high-dose subcutaneous methotrexate, 
but only in the short term; long-term follow-up would 
provide information about sustain ability and maintenance 
of disease control, and prevention of comorbidities.
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Prenatal imaging for diagnosis and prediction of 
neurodevelopmental outcomes in fetuses with brain 
malformations is a substantial challenge. Accurate 
diagnosis of brain abnormalities has important 
therapeutic implications. Consequently, it is essential that 
tools used for prenatal diagnosis are rigorously evaluated. 
The standard of care is prenatal ultrasound, but in-
utero MRI (iuMRI) has been a developing adjunct to 
prenatal ultrasound for the past 20 years.1 This process is 
increasingly used to image the fetal brain after anomalies 
are recorded during screening or diagnostic prenatal 
ultrasounds. The most common brain malformations 
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in which iuMRI is used include mild ventriculomegaly, 
agenesis of the corpus callosum, and defects in the 
posterior fossa. Proponents for iuMRI have argued that 
it oﬀ ers clinicians greater visualisation of the ventricular 
walls, germinal matrix, and developing white matter, and 
improved tissue contrast compared with conventional 
ultrasound.2 iuMRI might provide additional information 
that greatly informs patient counselling and clinical 
decision making. However, iuMRI also has its drawbacks. 
In centres where specialised neurosonography is 
available, iuMRI might oﬀ er limited improvement to 
clinical decision making.3 Moreover, iuMRI might have 
limited accuracy before 24 weeks of gestation, the 
gestational age at which pregnancy termination is often 
restricted. Finally, no cost-eﬀ ective assessment has been 
done to determine how iuMRI impacts the health-care 
system. The excellent MERIDIAN study4 published in 
The Lancet goes a long way to addressing these questions.
The MERIDIAN study was a multicentre, prospective 
cohort trial aimed to assess the ability of iuMRI to 
improve diagnostic performance, clinical impact, and 
acceptability for patients. 911 fetuses were recruited 
from 16 sites across the UK, of which 829 had a successful 
iuMRI. Most fetuses (369 [65%] of 570 who had iuMRI 
within 2 weeks) were less than 24 weeks gestation. 
Fetuses with identiﬁ ed intracranial abnormalities on 
ultrasound underwent iuMRI, mostly within 2 weeks of 
the ultrasound scan. An interesting component of the 
design is that radiologists doing iuMRI were not masked 
to the ultrasound diagnosis. Patients were also unblinded 
to the modality. Although this approach might introduce 
bias when determining which imaging modality is 
more accurate for prenatal diagnosis, it is reﬂ ective 
of clinical practice. Additionally, the radiologists were 
explicitly expected to compare the results of the diﬀ erent 
modalities, and these results were compared with the 
outcome reference diagnosis from post-mortem MRI, 
autopsy, postnatal CT, postnatal transcranial ultrasound, 
or postnatal MRI. Despite this methodological framework 
and its limitations, the results are clear and important.
The primary ﬁ nding is that diagnostic accuracy of iuMRI 
with respect to the outcome reference diagnosis improves 
by 23% (95% CI 18–27) up to 24 weeks gestation and 
by 29% (23–36) at 24 weeks and older when compared 
with ultrasound. Although that in itself is statistically 
signiﬁ cant, these ﬁ ndings also have important clinical 
implications that were characterised in the study. The 
radiologists had greater diagnostic conﬁ dence in the 
iuMRI and this translated into changes in the prognosis 
oﬀ ered to the families. These changes moved the 
prognosis from a category of uncertainty. Crucially, there 
were almost as many changes to a favourable prognosis 
group as there was to an unfavourable prognosis group. 
Unsurprisingly, patient counselling was also aﬀ ected by 
the increase in proportion of patients who were removed 
from categories of uncertainty and there was an increase 
in the number of terminations of pregnancy that were 
oﬀ ered. Overall, iuMRI was acceptable to the mothers 
with 95% of mothers willing to have an iuMRI in another 
pregnancy. 
These headline ﬁ ndings are important, but there are 
details that are not available in this Article. For example, 
there are no example images of how diagnoses and 
prognoses changed with iuMRI and no details on exactly 
how diagnoses changed.
It will be important to follow these children through 
paediatric neurology clinics to map the original 
structural abnormalities onto later developmental and 
neurological outcomes. These ﬁ ndings will ultimately 
reﬁ ne the ability of fetal medicine providers to 
prognosticate accurately and reliably oﬀ er terminations 
of pregnancy. An important question remains; if iuMRI 
is diagnostically superior to ultrasound scanning then 
there are probably fetuses with normal ultrasound 
scans that have signiﬁ cant structural abnormalities 
on iuMRI. However, it is currently not feasible to scan 
all pregnancies with MRI and it is unclear whether the 
health economics will ever justify such an approach. 
Nevertheless, MERIDIAN strongly supports the view 
that iuMRI is an excellent technique, and it should be 
incorporated into clinical practice as soon as possible.
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On Jan 23, 2017, on his fourth day in oﬃ  ce, President 
Donald Trump signed an executive order imposing the 
global gag rule,1 an anti-abortion policy that under other 
conservative presidential administrations has caused 
serious disruptions to US overseas family planning 
eﬀ orts. Alarmingly, Trump’s order goes even further than 
in the past, with potentially devastating eﬀ ect.
The global gag rule, also known as the Mexico City 
policy, was devised in 1984 by the administration of 
Ronald Reagan to impose a draconian set of anti-abortion 
rules on US overseas family planning programmes.2 This 
policy banned US family planning funds from going to 
foreign non-governmental organisations (NGOs) that 
provide abortion services, counselling, or referrals, or 
advocate for liberalisation of their country’s abortion 
laws—even if they use non-US government funds for 
these activities. In 1984, and every time the global gag 
rule has been imposed since then, foreign governments 
were exempt for diplomatic reasons, as were US-based 
NGOs on constitutional grounds. 
To be clear, legislation was already in place in 1984, 
and is still in place now, that bans the use of US funds 
under the Foreign Assistance Act from paying “for 
the performance of abortion as a method of family 
planning”.3 But for anti-abortion activists this Helms 
Amendment, passed in 1973, did not go far enough; they 
wanted to limit any activity that could possibly enable or 
promote abortion. Hence, the global gag rule.
Under Trump’s order, the gag rule now applies not only 
to US bilateral family planning assistance (US$575 million 
for ﬁ scal year 2016),4 but also to all “global health 
assistance furnished by all departments or agencies”1—
encompassing an estimated $9·5 billion in foreign 
aid.5 Foreign NGOs that receive US funding to work on 
a broad range of health programmes in about 60 low-
income and middle-income countries—including on HIV/
AIDS, the Zika virus, malaria, tuberculosis, nutrition, and 
maternal and child health, among others—will potentially 
be subject to the same ideological restrictions that have 
hampered family planning aid at points in the past.6 
Thus, President Trump’s version of the global gag rule 
represents a wider attack on global health aid writ large. 
Adding to the widespread concern among US 
government agencies, global health NGOs, and advocates 
is the Trump administration’s failure to provide any 
guidance on the interpretation or application of the new 
policy. Those details may emerge in the coming weeks 
and months. But we already know that, when last in 
eﬀ ect, the gag rule crippled family planning programmes. 
Many foreign NGOs, as a matter of principle and out of 
dedication to the patients they serve, refused to let the 
US Government muzzle their abortion advocacy eﬀ orts 
or dictate what services or counselling they provided 
using their non-US funds. These health providers were 
forced to reduce staﬀ  and services, or even shut clinics.2 
As a result, many thousands of women no longer had 
access to family planning and reproductive health services 
from these clinics—sometimes the only provider of such 
services in the local community. Various actors, including 
the governments of Canada and the Netherlands, are 
mobilising to compensate for at least some of the 
damage that will be done by the gag rule. But the US is the 
largest funder of global health programmes worldwide,7 
and the disruption this aid eﬀ ort will suﬀ er is massive.
Moreover, there is no evidence that the global gag rule 
has ever resulted in its stated aim of reducing abortion. 
The ﬁ rst study to measure the eﬀ ect of the gag rule 
showed that this policy could actually have resulted in 
an increase in abortions.8 Another study assessed the 
gag rule in Ghana and found that because of declines in 
the availability of contraceptive services, both fertility 
and abortion rates were higher during the gag rule 
years than during non-gag rule years in rural and poor 
populations.9 This is consistent with anecdotal data that 
the gag rule’s main eﬀ ect has been to reduce women’s 
access to quality contraceptive services, thereby 
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